Wegovy vs. Farxiga

See how Wegovy and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Wegovy is a once-weekly injectable GLP-1 for weight loss and cardiovascular risk reduction, while Farxiga is a once-daily oral SGLT2 inhibitor for diabetes, heart failure, and kidney disease.

  • Wegovy's most common side effects are gastrointestinal, while Farxiga's are mostly genital and urinary infections.

  • Both drugs have cardiovascular benefits, but Wegovy targets heart risk tied to obesity while Farxiga targets heart failure and kidney decline in diabetes.

Wegovy vs. Farxiga Drug Summary

Wegovy

Wegovy is a GLP-1 receptor agonist given as a once-weekly injection. It is approved for chronic weight management in adults and adolescents with obesity or overweight plus a related health condition, and to lower cardiovascular risk in adults with heart disease and excess weight. Dosing starts low and increases every four weeks up to a 2.4 mg maintenance dose.

Farxiga

Farxiga is an SGLT2 inhibitor taken as a once-daily tablet. It is approved for blood sugar control in type 2 diabetes, plus reducing hospitalization and death from heart failure and slowing chronic kidney disease progression. Most patients start at 5 mg and may increase to 10 mg daily depending on the condition treated.

Wegovy vs. Farxiga Side Effects

Wegovy

Most common
Nausea (up to 44%)
Diarrhea (up to 30%)
Vomiting (up to 24%)
Constipation (up to 24%)

Farxiga

Most common
Female genital mycotic infections (up to 6.9%)
Nasopharyngitis (up to 6.3%)
Urinary tract infections (up to 4.3%)
Back pain (up to 4.2%)

Wegovy vs. Farxiga Dosage

Wegovy

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2.4 mg once weekly Week 17 onward
Dose changes 4 increases Every 4 weeks

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Wegovy vs. Farxiga Indications

Wegovy

Wegovy is FDA-approved for long-term weight management in adults and adolescents 12 and older who have obesity or are overweight with a related condition like high blood pressure or type 2 diabetes. It also carries approval for reducing major cardiovascular events in adults with established heart disease who are overweight or obese. It is not approved for treating diabetes itself.

  • Chronic weight management with obesity or overweight plus a weight-related condition

  • Approved for adolescents 12 and older

  • Reduces risk of heart attack, stroke, and cardiovascular death in adults with heart disease

  • Used alongside diet and exercise

Farxiga

Farxiga is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to reduce heart failure hospitalization and cardiovascular death, and to slow the progression of chronic kidney disease, regardless of diabetes status. It is not approved for weight loss.

  • Blood sugar control in type 2 diabetes, ages 10 and up

  • Reduces hospitalization and death from heart failure (reduced or preserved ejection fraction)

  • Slows kidney function decline in chronic kidney disease

  • Used with diet and exercise as part of diabetes care

Wegovy vs. Farxiga Pros and Cons

Wegovy

Wegovy delivers substantial weight loss and is the only anti-obesity medication with FDA approval to reduce cardiovascular events in overweight or obese adults with heart disease. It requires a weekly injection and a gradual dose increase over several months, and insurance coverage for weight loss indications can be inconsistent.

Pros

  • FDA-approved specifically to reduce cardiovascular events in overweight or obese adults with heart disease

  • Produces substantial weight loss, more than most other anti-obesity medications

  • Only needs to be injected once a week

Cons

  • Common gastrointestinal side effects like nausea and vomiting during dose increases

  • Boxed warning for thyroid C-cell tumor risk seen in animal studies

  • Requires an injection rather than a pill

  • Roughly $1,300 to $1,350 per month without insurance, before savings programs

Farxiga

Farxiga is a once-daily pill with years of real-world use and FDA approval across diabetes, heart failure, and chronic kidney disease. It produces only modest weight loss compared to Wegovy, and it carries its own risks like genital infections and volume depletion.

Pros

  • Taken as a once-daily oral tablet, no injections needed

  • Approved for four distinct conditions: diabetes, two types of heart failure, and chronic kidney disease

  • Long safety track record since FDA approval in 2014

Cons

  • Not intended for significant weight loss, effects are modest compared to Wegovy

  • Risk of genital yeast infections and urinary tract infections

  • Rare but serious risk of ketoacidosis and Fournier's gangrene

  • Not recommended for glycemic control in advanced kidney disease

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.